PetVivo Holdings Inc (PETV) - Net Assets
Based on the latest financial reports, PetVivo Holdings Inc (PETV) has net assets worth $3.73 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.89 Million) and total liabilities ($3.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PetVivo Holdings Inc (PETV) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.73 Million |
| % of Total Assets | 54.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -72.26% |
| Growth Volatility | 3310.0 |
PetVivo Holdings Inc - Net Assets Trend (2011–2025)
This chart illustrates how PetVivo Holdings Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PetVivo Holdings Inc (PETV) market capitalisation.
Annual Net Assets for PetVivo Holdings Inc (2011–2025)
The table below shows the annual net assets of PetVivo Holdings Inc from 2011 to 2025. Also explore PETV net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $4.22 Million | +515.09% |
| 2024-03-31 | $685.95K | -5.39% |
| 2023-03-31 | $725.02K | -87.89% |
| 2022-03-31 | $5.99 Million | +767.43% |
| 2021-03-31 | $-896.98K | +13.43% |
| 2020-03-31 | $-1.04 Million | -22.65% |
| 2019-03-31 | $-844.82K | -718.24% |
| 2018-03-31 | $136.65K | -83.33% |
| 2017-03-31 | $819.75K | -94.61% |
| 2016-03-31 | $15.21 Million | +9332.60% |
| 2015-03-31 | $161.25K | +153.43% |
| 2014-03-31 | $-301.81K | -63.57% |
| 2013-03-31 | $-184.51K | -3.88% |
| 2012-03-31 | $-177.62K | -136.86% |
| 2011-03-31 | $-74.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PetVivo Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9093505000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.18K | 0.57% |
| Other Components | $95.39 Million | 2260.91% |
| Total Equity | $4.22 Million | 100.00% |
PetVivo Holdings Inc Competitors by Market Cap
The table below lists competitors of PetVivo Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GFM Services Bhd
KLSE:0039
|
$35.26 Million |
|
K Way Information
TWO:5201
|
$35.27 Million |
|
Dongwoo Farm To Table Co.Ltd
KQ:088910
|
$35.30 Million |
|
DCM Nouvelle Limited
NSE:DCMNVL
|
$35.32 Million |
|
Wisr Ltd
AU:WZR
|
$35.23 Million |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
$35.23 Million |
|
Ecoplastic Corporation
KQ:038110
|
$35.23 Million |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
$35.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PetVivo Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 685,953 to 4,219,248, a change of 3,533,295 (515.1%).
- Net loss of 8,399,166 reduced equity.
- New share issuances of 3,868,100 increased equity.
- Other factors increased equity by 8,064,361.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.40 Million | -199.07% |
| Share Issuances | $3.87 Million | +91.68% |
| Other Changes | $8.06 Million | +191.13% |
| Total Change | $- | 515.09% |
Book Value vs Market Value Analysis
This analysis compares PetVivo Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | $-1.67 | $1.12 | x |
| 2012-03-31 | $-3.46 | $1.12 | x |
| 2013-03-31 | $-3.31 | $1.12 | x |
| 2014-03-31 | $-2.52 | $1.12 | x |
| 2016-03-31 | $-0.04 | $1.12 | x |
| 2017-03-31 | $-6.43 | $1.12 | x |
| 2018-03-31 | $0.04 | $1.12 | x |
| 2019-03-31 | $-0.18 | $1.12 | x |
| 2020-03-31 | $-0.19 | $1.12 | x |
| 2021-03-31 | $-0.14 | $1.12 | x |
| 2022-03-31 | $0.68 | $1.12 | x |
| 2023-03-31 | $0.07 | $1.12 | x |
| 2024-03-31 | $0.05 | $1.12 | x |
| 2025-03-31 | $0.21 | $1.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PetVivo Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -199.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -741.63%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 2.21x
- Recent ROE (-199.07%) is above the historical average (-384.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-255.94K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-84.87K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-67.76K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.96 Million |
| 2015 | -970.94% | 0.00% | 0.00x | 4.73x | $-1.58 Million |
| 2016 | 0.00% | -2087.59% | 0.00x | 0.00x | $-1.56 Million |
| 2017 | 0.00% | -218017.03% | 0.00x | 0.00x | $-14.18 Million |
| 2018 | -1710.48% | -154790.60% | 0.00x | 11.47x | $-2.35 Million |
| 2019 | 0.00% | -6104.70% | 0.11x | 0.00x | $-4.67 Million |
| 2020 | 0.00% | -58944.23% | 0.01x | 0.00x | $-2.01 Million |
| 2021 | 0.00% | -29824.89% | 0.02x | 0.00x | $-3.66 Million |
| 2022 | -82.55% | -4275.42% | 0.02x | 1.24x | $-5.54 Million |
| 2023 | -1200.20% | -948.77% | 0.38x | 3.36x | $-8.77 Million |
| 2024 | -1597.09% | -1130.92% | 0.31x | 4.54x | $-11.02 Million |
| 2025 | -199.07% | -741.63% | 0.12x | 2.21x | $-8.82 Million |
Industry Comparison
This section compares PetVivo Holdings Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $638,670,729
- Average return on equity (ROE) among peers: -85.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PetVivo Holdings Inc (PETV) | $3.73 Million | 0.00% | 0.85x | $35.24 Million |
| Abbott Laboratories (ABT) | $4.40 Billion | 38.41% | 1.14x | $177.76 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $11.55 Million |
| Aethlon Medical Inc (AEMD) | $-9.30 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $780.04 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.88 Million |
| Allurion Technologies, Inc. (ALUR) | $-32.31 Million | 0.00% | 0.00x | $1.19 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.16 Million |
| Artivion Inc (AORT) | $79.80 Million | -34.79% | 0.33x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $127.64 Million |
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for … Read more